King K, Younes A
Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Semin Oncol. 2000 Feb;27(1 Suppl 1):14-22.
Several trials of new salvage therapies for relapsed and refractory non-Hodgkin's lymphoma are based on ifosfamide and paclitaxel. These programs variably Induce clinical remissions and prepare patients for stem cell and bone marrow transplantations. Ifosfamide-containing regimens are also being evaluated in the treatment of newly diagnosed patients. However, no data exist with regard to paclitaxel-containing regimens outside salvage settings. This report reviews the effects of these compounds in the treatment of relapsed and refractory non-Hodgkin's lymphoma and proposes likely directions for future study.
几种针对复发难治性非霍奇金淋巴瘤的新挽救疗法试验都以异环磷酰胺和紫杉醇为基础。这些方案不同程度地诱导临床缓解，并为患者进行干细胞和骨髓移植做准备。含异环磷酰胺的方案也正在用于新诊断患者的治疗评估中。然而，在挽救治疗之外，关于含紫杉醇方案的数据尚不存在。本报告回顾了这些化合物在复发难治性非霍奇金淋巴瘤治疗中的作用，并提出了未来可能的研究方向。
